Borgeson Blake’s July 7 Sale Sparks Insider‑Selling Frenzy at Recursion Pharma

Insider Selling Hot‑Spot: Borgeson Blake’s July 7 2026 Transaction

Borgeson Blake, a former director of Recursion Pharmaceuticals, sold 40,000 Class A shares on July 7 at an average price of $3.96 under a Rule 10b‑5‑1 trading plan. The sale coincided with a modest 0.01 % uptick in the stock price and a 75 % increase in social‑media buzz, suggesting that the market is paying close attention to insider activity. In the broader context, Recursion’s share price has dipped 1 % over the week, 16.8 % higher month‑to‑date, but a 28.8 % decline year‑to‑date, with a P/E ratio of –3.39. The company’s valuation of roughly $2 billion sits in a sector still grappling with high R&D costs and regulatory uncertainty.

What the Current Sale Says About Investor Confidence

Blake’s sale is part of a pattern of regular trading over the past year: he has alternated between sizable purchases (e.g., 88,424 shares in mid‑June) and sizable sales, most often around $3–$4 per share. The most recent purchase in mid‑June raised his holdings to 6.26 million shares, after which he sold 30,000 shares at $3.68 in early June and 30,000 shares at $3.52 in early May. The timing of the July sale—shortly after the stock’s price had recovered from its 52‑week low—may indicate a tactical liquidation rather than a red‑flag signal of impending downside. Nonetheless, the consistent selling trend could signal that insiders are cashing in on a valuation that they perceive as over‑valued relative to the company’s earnings trajectory.

Implications for Investors and the Company’s Future

For equity holders, the current volume of insider selling—together with a positive sentiment score of +41 and high social‑media buzz—suggests that investors should monitor the stock’s short‑term volatility. A surge in selling could depress the price further unless offset by institutional buying or a breakthrough in Recursion’s drug‑development pipeline. Conversely, the steady accumulation of shares by other insiders (e.g., Dar Zavain’s 5,109‑share purchase) hints at continued confidence in the company’s long‑term prospects. The key will be whether Recursion can translate its AI‑driven research into commercially viable therapies that generate cash flow and improve its P/E profile.

Borgeson Blake: A Profile of Trading Behavior

Blake’s insider activity shows a disciplined use of a pre‑established trading plan, avoiding the appearance of market timing. He has purchased shares in July 2025 and early 2026 at zero cost (option exercise), then sold at modest premiums in subsequent months. His net position has remained large—over 6 million shares—indicating a long‑term stake that outweighs periodic sales. Historically, his sales have averaged around $3.5 per share, slightly below the current price of $3.72, suggesting that he may view the stock as under‑priced relative to intrinsic value. However, his consistent selling pattern also aligns with a strategy of gradual portfolio rebalancing rather than a single exit.

Conclusion

Borgeson Blake’s July 7 sale is a noteworthy event in a series of insider trades that reflect both confidence in Recursion’s technology and a pragmatic approach to liquidity. While the immediate impact on the share price may be modest, the cumulative effect of insider selling—set against a backdrop of positive social sentiment and rising buzz—calls for vigilant monitoring by investors. The company’s ability to convert its AI‑powered research into commercial success will ultimately determine whether the current selling pressure will be a temporary dip or a harbinger of deeper valuation adjustments.